HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Partnered Content
Report Store
UsernamePublicRestriction
Tags:
Health Coronavirus COVID-19 OTC Drugs

Post-COVID Strategy: Invest, Don’t Save, Even If There's A Second Lockdown

  • Interviews

Executive Summary

What should consumer health companies be doing as Europe comes out of lockdown? Invest in key brands, says Sempora Consulting's managing partner Tobias Brodtkorb, and consider seizing the opportunity presented by the long-term trend for natural OTCs, which has been accelerated by the coronavirus pandemic. 

You may also be interested in...



2020 In Review: HBW Insight’s Five Key Takeaways For The European OTC Industry

HBW Insight extracts five key lessons from 2020, the year the coronavirus pandemic swept its way across Europe. 

Understanding The Post-COVID Health Consumer

HBW Insight speaks to industry expert Paul Wardle - who worked on Pfizer's Viagra switch - about how data analytics can help firms extract the “beacons of insight” to create the consumer health brands of tomorrow.

German OTC Market Woes Continue

Germany's OTC market blues continue as the coronavirus lockdown bites into May. 

Table

View full table

Related Content

HBW Insight

Topics

Tags:
Health Coronavirus COVID-19 OTC Drugs
UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By